influenza
virus
among
import
human
pathogen
respons
annual
epidem
sporad
potenti
devast
pandem
humor
immun
respons
play
import
role
defens
virus
provid
protect
mainli
produc
antibodi
direct
hemagglutinin
ha
glycoprotein
howev
high
genet
variabl
allow
viru
evad
host
immun
respons
potenti
protect
offer
season
vaccin
emerg
resist
antivir
drug
recent
year
limit
option
avail
control
influenza
develop
altern
strategi
influenza
prophylaxi
therapi
therefor
urgent
need
studi
describ
human
monoclon
antibodi
recogn
highli
conserv
epitop
locat
stem
region
ha
abl
neutral
broad
spectrum
influenza
virus
belong
differ
subtyp
furthermor
describ
protect
activ
mice
lethal
challeng
virus
suggest
potenti
applic
treatment
influenza
viru
infect
season
influenza
caus
death
worldwid
year
infant
immunocompromis
individu
elderli
particularli
suscept
death
occur
latter
group
influenza
virus
also
caus
pandem
although
rare
recurr
event
histor
associ
high
level
morbid
mortal
prevent
vaccin
histor
effici
measur
influenza
control
approach
present
import
limit
due
accumul
antigen
mutat
viru
known
antigen
drift
vaccin
typic
elicit
potent
neutral
antibodi
respons
limit
specif
viral
strain
includ
prepar
close
relat
virus
reason
season
vaccin
need
annual
reformul
base
upon
forecast
viral
strain
circul
come
influenza
season
furthermor
influenza
vaccin
suboptim
immunogen
efficaci
group
highest
risk
sever
diseas
moreov
case
pandem
use
vaccin
limit
time
requir
develop
deploy
current
therapeut
regimen
influenza
virus
limit
two
class
drug
adamantan
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
howev
natur
andor
acquir
resist
drug
report
resist
adamantan
preval
among
season
avian
influenza
virus
significantli
reduc
use
sudden
widespread
emerg
resist
oseltamivir
among
prepandem
virus
rais
concern
current
therapeut
option
oseltamivir
resist
report
patient
infect
pandem
virus
highli
virul
virus
resist
zanamivir
rare
use
limit
patient
activ
inhal
often
exclud
young
children
impair
older
adult
patient
underli
airway
diseas
group
patient
vulner
seriou
influenza
infect
complic
altern
strategi
need
combat
constant
threat
pose
influenza
one
strategi
may
come
passiv
immunoprophylaxi
monoclon
antibodi
mab
recogn
broadli
conserv
influenza
epitop
endow
broadrang
neutral
activ
import
protect
antigen
surfac
influenza
viru
ha
whose
structur
divid
two
distinct
region
globular
head
respons
bind
sialic
acid
stem
region
contain
fusion
peptid
membran
anchor
domain
globular
head
constitut
subunit
lie
sever
epitop
target
neutral
antibodi
howev
mab
recogn
region
restrict
applic
due
antigen
drift
region
encount
contrast
stem
region
ha
form
mostli
subunit
rel
conserv
among
differ
influenza
subtyp
inde
could
repres
univers
target
develop
crossneutr
monoclon
antibodi
sever
human
heterosubtyp
neutral
mab
direct
ha
stem
region
protect
featur
anim
model
recent
describ
mab
recogn
epitop
locat
conserv
region
influenza
virus
ha
neutral
influenza
virus
block
fusion
viral
host
endosom
membran
mani
antiinfluenza
heterosubtyp
neutral
mab
util
germlin
gene
bind
hydrophob
region
ha
stem
use
complementari
determin
region
studi
describ
human
monoclon
antibodi
name
recogn
highli
conserv
epitop
stem
region
ha
featur
one
strongest
invitro
neutral
activ
describ
far
broad
spectrum
virus
belong
differ
influenza
subtyp
furthermor
describ
protect
activ
mice
lethal
challeng
virus
suggest
potenti
broadspectrum
monoclon
antibodi
treatment
influenza
viru
infect
previous
describ
fab
fragment
bind
stem
region
ha
neutral
test
isol
heavi
chain
variabl
region
use
gene
pair
light
chain
nucleotid
sequenc
homolog
germlin
sequenc
vh
gene
vl
gene
demonstr
origin
somat
mutat
process
studi
order
better
character
neutral
activ
produc
whole
molecul
use
bd
baculogold
system
whole
igg
molecul
test
fluoresc
inhibit
assay
infecti
foci
format
reduct
assay
plaqu
reduct
assay
human
swine
avian
influenza
virus
belong
phylogenet
group
group
result
obtain
show
igg
stronger
neutral
activ
compar
fab
tabl
inde
igg
neutral
test
virus
belong
group
except
viru
strain
belong
subtyp
half
maxim
inhibitori
concentr
rang
mgml
tabl
figur
contrari
show
neutral
activ
virus
belong
group
figur
data
suggest
epitop
recogn
conserv
among
group
virus
therapeut
efficaci
challeng
mous
model
determin
whether
invitro
neutral
activ
display
would
predict
protect
efficaci
invivo
balbc
mice
inocul
intranas
fifti
percent
lethal
dose
awilson
viru
treat
hour
later
mgkg
mab
use
control
mg
kg
protect
mice
lethal
challeng
dosedepend
manner
provid
protect
death
anim
receiv
mgkg
antibodi
protect
anim
receiv
mgkg
figur
consist
invitro
neutral
activ
mgkg
afford
protect
lethal
viru
challeng
figur
wherea
control
mice
rapidli
succumb
infect
day
postchalleng
pc
surviv
mice
remain
healthi
show
minim
bodi
weight
loss
maximum
weight
loss
group
group
observ
period
conclus
experi
mean
bodi
weight
loss
treat
mice
challeng
viru
figur
mice
infect
regain
full
bodi
weight
figur
gain
insight
kinet
viral
neutral
vivo
mice
group
euthan
day
pc
viral
titer
determin
whole
lung
tissu
significantli
reduc
viru
titer
lung
mice
infect
approxim
fold
mgkg
fold
mgkg
figur
reduct
pulmonari
viru
titer
note
mice
challeng
viru
receiv
mgkg
figur
taken
togeth
result
indic
surviv
associ
import
reduct
viru
burden
lung
mice
treat
reduct
concord
invivo
activ
order
better
defin
ha
region
recogn
sever
approach
use
firstli
hemagglutin
inhibit
hi
activ
evalu
result
hi
titr
mgml
mgml
viru
respect
secondli
evalu
recogn
epitop
ha
stem
region
competit
assay
apuerto
human
epitheli
kidney
transfect
cell
perform
commerci
avail
mous
monoclon
antibodi
takara
bio
inc
otsu
shiga
japan
bind
epitop
ha
stem
region
result
obtain
show
complet
inhibit
bind
figur
evid
bind
epitop
ha
stem
region
given
lack
proteas
suscept
ha
low
ph
presenc
exposur
low
ph
follow
trypsin
digest
result
degrad
ha
contrast
ha
pretreat
ha
retain
proteas
resist
prefus
form
figur
taken
togeth
preliminari
data
suggest
epitop
recogn
local
ha
stem
region
close
proxim
ha
globular
head
base
competit
assay
result
larg
panel
ha
mutant
carri
alanin
substitut
gener
bind
mutant
evalu
fac
analysi
data
obtain
reveal
bind
decreas
mutant
mutant
locat
sequenc
number
refer
genbank
access
number
importantli
residu
extrem
conserv
among
virus
belong
subtyp
span
also
highli
conserv
subtyp
figur
mutat
effect
antibodi
bind
ha
figur
exclud
possibl
reduc
bind
ha
due
reduc
express
ha
cell
surfac
perform
fac
analysi
wildtyp
ha
mutant
ha
stain
mous
antiinfluenza
ha
subtyp
monoclon
antibodi
antibodi
direct
linear
epitop
order
evalu
express
level
ha
cell
surfac
shown
figur
ha
mutant
express
cell
surfac
similar
level
wild
type
ha
consist
great
phylogenet
distanc
amino
acid
differ
posit
test
viral
strain
belong
subtyp
viral
strain
belong
subtyp
may
least
partial
explain
lack
neutral
activ
strain
base
result
obtain
alanin
scan
studi
insilico
analysi
ha
crystal
structur
pdb
id
code
carri
analysi
confirm
residu
identifi
lie
stem
region
ha
belong
subunit
expos
surfac
ha
molecul
figur
studi
character
human
mab
igg
direct
influenza
virus
previous
describ
fab
fragment
igg
neutral
broad
spectrum
virus
belong
differ
influenza
subtyp
character
lowest
mean
valu
describ
date
heterosubtyp
mab
influenza
subtyp
test
studi
tabl
furthermor
igg
endow
stronger
neutral
activ
compar
monoval
molecul
tabl
inde
well
document
literatur
bival
igg
molecul
may
essenti
featur
biolog
activ
mab
mostli
due
increas
antibodi
avid
increas
avid
may
also
play
import
role
prophylact
therapeut
applic
antibodi
allow
administr
smaller
amount
compar
fab
fragment
addit
whole
igg
molecul
longer
halflif
fragment
consequ
prolong
effect
molecul
reason
use
igg
treat
mice
infect
virus
data
obtain
show
protect
mice
viru
lethal
challeng
suggest
potenti
applic
treatment
influenza
viru
infect
antiinfluenza
heterosubtyp
neutral
mab
describ
thu
far
deriv
germlin
bind
conserv
epitop
ha
stem
region
present
group
influenza
virus
bind
mainli
highli
hydrophob
amino
acid
residu
heavi
chain
instead
heavi
chain
variabl
region
result
gene
rearrang
gene
segment
demonstr
despit
preferenti
usag
heterosubtyp
respons
influenza
ha
invivo
heterosubtyp
protect
may
confer
also
non
deriv
ab
recogn
novel
broadli
neutral
epitop
ha
stem
region
highli
conserv
among
group
subtyp
confirm
human
particular
region
broadli
share
among
isol
span
subtyp
respons
pandem
highli
pathogen
potenti
pandem
influenza
viru
final
protect
mice
given
lethal
challeng
either
viru
suggest
great
potenti
broadspectrum
monoclon
antibodi
vivo
treatment
influenza
viru
infect
taken
togeth
data
underlin
import
develop
antiinfluenza
strategi
base
passiv
immun
studi
necessari
defin
effect
prophylact
therapeut
administr
protocol
final
data
detail
definit
epitop
recogn
could
also
use
develop
new
vaccin
strategi
abl
elicit
humor
immun
respons
direct
key
region
influenza
ha
protein
studi
carri
strict
accord
recommend
guid
care
use
amino
acid
sequenc
conserv
hemagglutinin
group
subtyp
region
bound
circl
residu
indic
percentag
bind
ha
alanin
mutant
compar
bind
wildtyp
ha
red
bind
yellow
bind
blue
bind
sequenc
number
base
apuerto
code
region
genbank
access
number
subtyp
neutral
indic
green
left
one
neutral
indic
red
recombin
ha
asouth
pandem
strain
previous
shown
bound
b
anew
previous
shown
neutral
fab
fragment
previous
describ
molecular
clone
human
monoclon
antibodi
fab
fragment
name
antiinfluenza
antibodi
direct
subtyp
ha
name
antihcv
glycoprotein
antibodi
name
produc
purifi
ident
procedur
use
control
experi
follow
human
refer
strain
acquir
american
type
cultur
collect
mgml
streptomycin
gibco
invitrogen
carlsbad
ca
usa
mgml
tpcktrypsin
roch
appli
scienc
isol
analog
grown
newborn
swine
kidney
nsk
cell
kindli
provid
zooprophylact
institut
brescia
itali
confluenc
cell
mem
supplement
mgml
serumfre
tpcktrypsin
infect
strain
moi
hour
infect
cell
wash
phosphat
buffer
salin
pb
mem
supplement
mgml
tpcktrypsin
ad
cell
incub
atmospher
cell
observ
daili
monitor
cytopath
effect
usual
hour
supernat
collect
centrifug
rcf
minut
elimin
cell
debri
filter
mm
filter
millipor
billerica
usa
supernat
aliquot
store
cellfre
viru
well
serial
dilut
mgml
igg
preincub
hour
median
tissu
cultur
infect
dose
viru
follow
incub
ml
mix
antibodyviru
ad
cell
incub
anoth
hour
end
incub
cell
wash
pb
ml
mem
tpcktrypsin
mgml
ad
well
cell
incub
hour
wash
pb
fix
permeabil
icecold
ethanol
cell
incub
antiinfluenza
mous
antibodi
argen
shirley
ny
usa
minut
humid
chamber
cell
wash
pb
incub
minut
dark
humid
chamber
fitcconjug
secondari
antibodi
argen
shirley
ny
usa
nuclei
stain
obtain
hoechst
sigma
aldrich
infect
control
without
antibodi
includ
well
neg
control
antibodi
neutral
assay
perform
triplic
repeat
two
differ
session
neutral
activ
antibodi
concentr
express
percentag
reduct
fluoresc
nuclei
compar
nuclei
count
infect
control
nuclei
count
perform
use
ge
healthcar
cell
analyz
autom
epifluoresc
base
microscop
system
neutral
curv
fit
nonlinear
regress
graphpad
prism
softwar
allow
calcul
virus
also
test
plaqu
reduct
assay
previous
describ
briefli
neutral
assay
carri
well
plate
use
mdck
cell
cellswel
two
dilut
mgml
igg
preincub
hour
viru
follow
incub
ml
virusantibodi
mix
ad
mdck
monolay
plate
incub
hour
medium
remov
monolay
wash
twice
pb
two
ml
memagaros
supplement
penicillin
mgml
gibco
invitrogen
carlsbad
ca
usa
streptomycin
mgml
gibco
invitrogen
carlsbad
ca
usa
lglutamin
mm
gibco
invitrogen
carlsbad
ca
usa
trypsin
mgml
roch
appli
scienc
ad
well
plate
incub
hour
incub
agaros
medium
remov
well
ml
methanolcryst
violet
wv
ad
well
room
temperatur
final
well
wash
tap
water
dri
infect
control
without
antibodi
ad
well
neg
control
mab
neutral
determin
count
pfu
reduct
presenc
antibodi
compar
infect
control
infecti
foci
format
reduct
assay
follow
virus
viral
isol
titrat
establish
work
dilut
produc
foci
form
unit
per
well
tissu
cultur
plate
neutral
assay
carri
well
plate
use
cell
serial
dilut
mgml
igg
preincub
hour
subset
virus
follow
incub
ml
antibodyviru
mix
ad
cell
incub
anoth
hour
end
incub
cell
wash
twice
pb
ml
viru
growth
media
contain
mgml
tpck
treat
trypsin
ad
cell
incub
hour
wash
pb
fix
permeabil
ice
cold
methanolacet
acid
min
cell
incub
antinp
antibodi
millipor
billerica
usa
minut
cell
wash
incub
minut
mous
hrpconjug
secondari
antibodi
true
blue
chromogen
substrat
kpl
use
count
number
foci
femal
balbc
mice
purchas
week
age
charl
river
co
wilmington
mice
maintain
specif
pathogenfre
barrier
facil
anim
experi
procedur
conform
protocol
approv
center
diseas
control
prevent
cdc
atlanta
ga
usa
viru
four
group
mice
inocul
intranas
awilson
viru
ml
volum
h
inocul
grade
dose
mgkg
control
antibodi
mgkg
administr
mice
intraperiton
inject
final
volum
ml
subset
six
mice
group
weigh
day
viru
challeng
observ
weigh
everi
day
week
inocul
mice
lost
initi
bodi
weight
euthan
subset
four
anim
treat
mab
euthan
day
inocul
whole
lung
homogen
ml
steril
pb
viru
titer
lung
tissu
homogen
determin
plaqu
titrat
mdck
cell
monolay
cultur
hemagglutin
hi
assay
hi
test
use
mab
control
antibodi
live
virus
perform
accord
standard
protocol
briefli
serial
dilut
purifi
mab
pb
perform
initi
concentr
mgml
posit
neg
control
ferret
sera
dilut
initi
receptordestroy
enzym
vibrio
cholera
denka
seiken
tokyo
serial
dilut
control
sera
mab
preincub
ha
unit
viru
per
well
viru
turkey
red
blood
cell
rbc
ad
final
concentr
wherea
hors
rbc
use
suspens
viru
normal
ferret
serum
gave
valu
less
specif
hi
activ
mab
calcul
lowest
concentr
mab
display
hi
activ
proteas
suscept
assay
reaction
contain
ml
antiinfluenza
vaccin
season
inflexalvcrucel
contain
ng
ha
ml
antiinfluenza
vaccin
season
combin
fold
molar
excess
titron
ad
prevent
aggreg
postfus
ha
ph
lower
sampl
except
control
use
citric
acid
ph
reaction
mix
briefli
centrifug
incub
one
hour
incub
reaction
equilibr
room
temperatur
ph
neutral
addit
tri
ph
actual
ph
reach
determin
parallel
use
larger
buffer
volum
without
protein
trypsin
ad
sampl
except
control
final
ratio
mass
sampl
digest
overnight
nonreduc
sd
buffer
ad
reaction
sampl
boil
minut
load
nonreduc
polyacrilamid
precast
gel
biorad
itali
run
sampl
transfer
pvdf
membran
perkinelm
belgium
hour
membran
block
fat
milk
pbst
h
room
temperatur
wash
three
time
pbst
human
antiha
monoclon
antibodi
recogn
use
primari
antibodi
mgml
fat
milkpbst
membran
incub
hour
room
temperatur
wash
three
time
pbst
secondari
antihuman
antibodi
ad
incub
h
room
temperatur
incub
membran
wash
substrat
solut
supersignalh
west
pico
chemiluminesc
substrat
pierc
ad
incub
min
determin
ph
requir
convert
ha
postfus
form
ph
titrat
use
assay
describ
perform
sampl
expos
rang
ph
condit
ph
neutral
process
describ
apuerto
hemagglutinin
amplifi
previous
describ
use
follow
pcr
primer
caccatgaaggcaaacctactggtcctgttatgtg
tcagatgcatattctgcactgcaaagatccattaga
pcr
product
clone
pcdna
vector
invitrogen
carlsbad
ca
usa
subsequ
ha
alanin
mutant
gener
use
gene
tailor
sitedirect
mutagenesi
system
invitrogen
carlsbad
ca
usa
total
mutant
gener
subunit
subunit
sequenc
number
refer
genbank
access
number
bind
activ
assay
use
fulllength
wild
type
mutant
human
epitheli
kidney
cell
atcc
transfect
well
plate
corn
corn
ny
usa
cellswel
mg
pcdna
vector
contain
ha
nucleotid
sequenc
describ
centrifug
fixat
paraformaldehyd
minut
rt
transfect
cell
incub
minut
room
temperatur
conform
control
mgml
addit
isotyp
control
mgml
introduc
well
untransfect
cell
mous
antiinfluenza
ha
subtyp
monoclon
antibodi
genetex
inc
irvin
ca
usa
direct
linear
epitop
evalu
transfect
effici
express
level
ha
cell
wash
pb
incub
minut
room
temperatur
fitcconjug
antihuman
sigma
aldrich
antimous
argen
shirley
ny
usa
antibodi
afterward
cell
wash
pb
analyz
fac
fac
data
analyz
use
softwar
weasel
w
walereliza
hall
institut
medic
research
parkvil
victoria
australia
bind
differ
hamut
express
bind
percentag
compar
wildtyp
data
show
pnsia
bind
decreas
wild
type
ha
ha
mutant
obtain
normal
pnsia
bind
valu
correspond
express
control
valu
competit
assay
serial
dilut
use
combin
fix
concentr
mgml
mous
monoclon
antibodi
takara
bio
inc
otsu
shiga
japan
bind
epitop
ha
stem
region
sequenc
analysi
follow
softwar
packag
use
seqscap
appli
biosystem
clustalx
tobi
gibson
bio
edit
tom
hall
ibi
therapeut
treeview
gubusoft
molecular
visual
render
ucsf
chimera
packag
resourc
biocomput
visual
informat
univers
california
rasmol
roger
sayl
jmol
jmol
opensourc
java
viewer
chemic
structur
http
wwwjmolorg
unit
state
nation
librari
medicin
nlm
use
final
data
analysi
graphic
edit
graphpad
prism
use
figur
neutral
assay
group
influenza
virus
doserespons
curv
fit
nonlinear
regress
report
igg
neutral
group
influenza
virus
result
fluoresc
inhibit
assay
b
plaqu
reduct
assay
c
infecti
foci
format
reduct
assay
data
least
two
differ
experi
viru
report
point
perform
triplic
pdf
figur
influenza
hemagglutinin
unroot
phylogenet
tree
viral
strain
test
neutral
assay
viral
isol
belong
group
group
divid
two
differ
box
subtyp
neutral
indic
green
one
neutral
indic
red
report
text
abl
neutral
group
virus
test
studi
except
strain
neutral
activ
detect
virus
test
recombin
ha
asouth
pandem
strain
previous
shown
bound
anew
previous
shown
neutral
fab
fragment
pdf
figur
competit
assay
graphic
represent
cell
stain
flow
cytometr
analysi
cell
transfect
pcdna
vector
contain
perform
serial
dilut
use
combin
fix
concentr
mgml
blue
line
monoclon
antibodi
direct
ha
globular
head
use
competit
neg
control
pink
line
pdf
figur
ha
mutant
determin
decreas
bind
ha
express
level
wild
type
ha
cell
surfac
fac
curv
show
bind
ha
antibodi
direct
linear
epitop
untransfect
cell
ha
wildtyp
hamut
white
red
curv
repres
graph
respect
bind
antiha
express
control
untransfect
cell
wild
type
differ
colour
curv
repres
differ
mutant
pdf
